OneMedNet Corporation completed a 1.5‑million‑patient, 4‑million‑encounter real‑world data feed to a leading analytics partner on January 16 2026, delivering 1.49 billion data points across structured and unstructured domains. The feed, supplied under the company’s subscription model, demonstrates its ability to provide regulatory‑grade datasets that include practitioner notes, immunizations, conditions, medications, encounters, and observations.
The delivery marks a key milestone in OneMedNet’s strategy to convert one‑time data transactions into recurring annual recurring revenue (ARR). By enabling the partner to ingest, harmonize, and operationalize the data, the feed clears a critical step toward production deployment and commercial scale for both parties. The partnership leverages Palantir’s Foundry platform to automate data ingestion and scale the delivery, positioning OneMedNet to expand its ecosystem and pursue additional enterprise customers.
While the operational achievement is significant, the company’s broader financial picture remains challenging. Recent filings show negative operating margins and a distressed financial strength rating, underscoring that the business is still working to achieve profitability. Management has highlighted that the company is investing heavily in AI‑driven analytics and network expansion, which are expected to drive future revenue growth but also increase short‑term costs.
In the three months leading up to November 2025, OneMedNet reported a 38 % increase in patient records and a 37 % rise in clinical exams, and an 815 % jump in bookings in Q3 2025 versus Q3 2024. These growth metrics illustrate the company’s expanding data footprint, but the company’s margin compression reflects the cost of scaling and the need to invest in technology and talent.
Analysts note that the successful data feed validates OneMedNet’s subscription model and its partnership with Palantir, but they also caution that the company’s financial headwinds could limit its ability to capitalize on the growing real‑world evidence market, projected to reach nearly $10.8 billion by 2030. The company’s focus on AI and data monetization positions it well for long‑term growth, but investors will watch how it balances investment with profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.